Security key
86150R107
Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share (STOK)
CUSIP: 86150R107
Q3 2020 13F Holders as of 30 Sep 2020
- Security type / class
- Equity / Common Stock, $0.0001 par value per share
- Total 13F shares
- 34,632,372
- Total 13F value
- $1,159,842,494
- Share change
- -315,920
- SEC-reported price per share
- $33.49
- Number of holders
- 89
- Value change
- +$2,937,942
- Number of buys
- 37
- Number of sells
- 33
- Shares outstanding
- 58,810,778
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2020
Institutions
89
Top holders
10
STOK full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q4 2020
Previous quarter: Q2 2020
Stoke Therapeutics, Inc. SEC filings
Stoke Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 86150R107
Recent filing periods:
Ownership snapshot
Top reported holders of STOK - Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ATP Life Science Ventures...
Disclosed value leader
ATP Life Science Ventures...
Comparable rows
15/15
Latest evidence
30 Jun 2020
13F
Lead comparable stake: 29%
Showing 1-6 of 15 holder rows.
Quick read
ATP Life Science Ventures, L.P. leads the comparable SEC ownership view at 29%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ATP Life Science Ventures, L.P.'s linked filing trail.
Comparable ownership
Top 5
ATP Life Science Ventures, L.P.
29%
RTW INVESTMENTS, LP
6%
Redmile Group, LLC
4.3%
Cormorant Asset Management, LP
2.9%
GILDER GAGNON HOWE & CO LLC
2.7%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ATP Life Science Ventures, L.P. |
13F
Company
|
29%
|
$391,802,000
16,786,713 shares
|
— | 30 Jun 2020 |
| RTW INVESTMENTS, LP |
13F
Company
|
6%
|
$84,459,000
3,544,248 shares
|
— | 30 Jun 2020 |
| Redmile Group, LLC |
13F
Company
|
4.3%
|
$59,630,000
2,502,306 shares
|
— | 30 Jun 2020 |
| Cormorant Asset Management, LP |
13F
Company
|
2.9%
|
$40,542,000
1,701,292 shares
|
— | 30 Jun 2020 |
| GILDER GAGNON HOWE & CO LLC |
13F
Company
|
2.7%
|
$37,403,000
1,569,564 shares
|
— | 30 Jun 2020 |
| VANGUARD GROUP INC |
13F
Company
|
2.2%
|
$30,462,000
1,278,341 shares
|
— | 30 Jun 2020 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2020
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
89
Shares
34,632,372
Rows available
89
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2020 vs Q2 2020 Across Filers
Q2 2020 holders
70
Q3 2020 holders
89
Holder diff
19
| Investor | Q2 2020 Shares | Q3 2020 Shares | Share Diff | Share Chg % | Q2 2020 value | Q3 2020 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend